
-
Maresca non-committal over Sancho's future at Chelsea
-
WHO facing $2.5-bn gap even after slashing budget: report
-
Real Madrid coach Ancelotti tells tax trial did not seek to defraud
-
Chinese tourists pine for Taiwan's return as Beijing jets surround island
-
Singapore detains teenage boy allegedly planning to kill Muslims
-
What is the 'Qatargate' scandal roiling Israel?
-
AI coming for anime but Ghibli's Miyazaki irreplaceable, son says
-
Swedish insurer drops $160 mn Tesla stake over labour rights
-
Hunger returns to Gaza as Israeli blockade forces bakeries shut
-
Rubio heads to Europe as transatlantic tensions soar
-
Like 'living in hell': Quake-hit Mandalay monastery clears away rubble
-
'Give me a break': Trump tariffs threaten Japan auto sector
-
US approves $5.58 bn fighter jet sale to Philippines
-
Tsunoda embracing pressure of Red Bull debut at home Japanese GP
-
'Outstanding' Hay shines as New Zealand seal Pakistan ODI series
-
El Salvador's Bukele flaunts 'iron fist' alliance with Trump
-
Stock markets mixed as uncertainty rules ahead of Trump tariffs
-
China probes for key target weak spots with 'paralysing' Taiwan drills
-
'Top Gun' and Batman star Val Kilmer dies aged 65: New York Times
-
US lawmakers seek to rename street for Hong Kong's jailed Jimmy Lai
-
Greece to spend big on 'historic' military shake up
-
Trump faces first electoral setback after Wisconsin Supreme Court vote
-
Hay shines as New Zealand beat Pakistan for ODI series win
-
Israel says expands Gaza offensive to seize 'large areas'
-
Curry drops 52 as Warriors win, Jokic bags career-high 61 in Denver loss
-
South Korea mobilising 'all resources' for violence-free Yoon verdict
-
Myanmar quake victim rescued after 5 days as aid calls grow
-
Real Madrid coach Ancelotti tax fraud trial set to begin
-
Warner showcases 'Superman' reboot, new DiCaprio film
-
'Incredible' Curry scores 52 as Warriors down Grizzlies, Bucks edge Suns
-
Asian markets edge up but uncertainty rules ahead of Trump tariffs
-
Nintendo's megahit Switch console: what to know
-
Nintendo to unveil upgrade to best-selling Switch console
-
China practises hitting key ports, energy sites in Taiwan drills
-
Oil, sand and speed: Saudi gearheads take on towering dunes
-
All eyes on Tsunoda at Japan GP after ruthless Red Bull move
-
'Image whisperers' bring vision to the blind at Red Cross museum
-
Hay shines as New Zealand make 292-8 in Pakistan ODI
-
Other governments 'weaponising' Trump language to attack NGOs: rights groups
-
UK imposes online entry permit on European visitors
-
How a Brazilian chief is staving off Amazon destruction
-
Meme politics: White House embraces aggressive alt-right online culture
-
China launches military drills in Taiwan Strait
-
US senator smashes record with 25-hour anti-Trump speech
-
Brazil binman finds newborn baby on garbage route
-
US senator smashes record with marathon anti-Trump speech
-
Trump advisor Waltz faces new pressure over Gmail usage
-
NHI Announces $63.5 Million Senior Housing Investment
-
Miami Church Covers 100% of Uber Rides to Easter Service-Tips Included
-
Niger junta frees ministers of overthrown government

EU to unveil reforms for cheaper drugs
The EU on Wednesday is to unveil a long-awaited proposed reform of legislation governing pharmaceutical drugs to make them cheaper, prevent shortages and speed up delivery of new compounds.
The overhaul aims to bring "timely and equitable access for patients to affordable drugs" in the bloc, EU health commissioner Stella Kyriakides tweeted.
The reform is the biggest in two decades, and has in part been informed by Brussels' swift, concerted action during the Covid pandemic that underscored the benefits of less-burdensome procedures, greater transparency and joint measures.
The pharmaceutical industry has been intensively lobbying ahead of the presentation of the proposals.
A leak in February of a draft version of them sparked criticism from companies worried that the exclusive period they had over selling new drugs could be shortened from 10 years to eight.
The European Federation of Pharmaceutical Industries and Associations warned against steps that could constrain innovation.
While the European Commission aims to bring down the cost of medicines, it doesn't have the power to set prices in the European Union.
That is the prerogative of national governments who negotiate with pharmaceutical groups.
The EU executive is also intent on tackling shortages of drugs for rare diseases, and unequal access to medicines across the 27-nation bloc, especially in eastern member states.
Another challenge to be tackled is increasing microbial resistance to existing antibiotics, which each year leads to 35,000 deaths in the European Union.
Because antibiotics are meant to be taken in moderate, defined doses they are less lucrative to pharmaceutical companies than blockbuster drugs.
- Voucher system -
To address that problem, the commission is looking at introducing transferable vouchers that would allow a company coming up with a new, effective antibiotic to apply a lengthened period of exclusivity to another more profitable drug, or to sell that right to another company.
Around half the EU member states, including France, Belgium and the Netherlands, are wary of that idea though, worried it would weigh on national health systems.
The European Consumer Organisation has also come out against that proposal.
"But so far, no one has proposed a better system," said one EU lawmaker, Peter Liese, who is also a medical doctor.
He said that virtually no new antibiotic had been produced in 20 years. On this issue and the others the commission is proposing, "innovation-friendly regulation is indispensable," he said.
The commission also wants a faster approval process to get new drugs to market faster, as happened with Covid vaccines.
And it is suggesting a measure to force companies to be more transparent about the stocks of drugs they have, so that any looming shortfalls can be tackled earlier on.
For Pauline Londeix, co-founder of OTMeds, a French group monitoring levels of transparency on drugs policies, "a centralised system of alerts on shortages goes in the right direction but is not enough in itself".
She argues that the EU should consider "coordinated action at the European level for the part-public production of essential medicines".
L.Durand--AMWN